Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CERo Therapeutics Holdings ( (CERO) ) just unveiled an announcement.
CERo Therapeutics, an innovative immunotherapy company, has appointed Chris Ehrlich as the new CEO, highlighting his extensive industry experience. Ehrlich aims to advance CERo’s pioneering T cell therapeutics, with plans to introduce CER-1236 into clinical trials for solid tumors and AML by early 2025. This strategic move underscores CERo’s commitment to revolutionizing cancer treatment through its unique CER-T technology, potentially offering broader applications than existing CAR-T therapies.
Learn more about CERO stock on TipRanks’ Stock Analysis page.
